Patrick Ingiliz

Summary

Country: Germany

Publications

  1. ncbi request reprint Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients
    Patrick Ingiliz
    Hepatology Department, Pitie Salpetriere Hospital, Paris, France
    Antivir Ther 13:895-900. 2008
  2. doi request reprint Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy
    Patrick Ingiliz
    Hepatology Department, AP HP, GH Pitié Salpétrière, Paris, France
    Hepatology 49:436-42. 2009
  3. pmc Applicability and variability of liver stiffness measurements according to probe position
    Patrick Ingiliz
    AP HP Hospital Group Pitié Salpêtrière, Hepatology Department, Cedex 13, Paris 75651, France
    World J Gastroenterol 15:3398-404. 2009
  4. doi request reprint Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysis
    Patrick Ingiliz
    Hepatology Department, Pitie Salpetriere Hospital, Paris, France
    J Hepatol 56:49-54. 2012
  5. pmc Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers
    Thierry Poynard
    APHP Groupe Hospitalier Pitié Salpétrière, Universite Paris VI, CNRS UMR, Paris, France
    PLoS ONE 3:e3857. 2008
  6. pmc An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS UMR 8149, Paris, France
    PLoS ONE 3:e2573. 2008
  7. pmc Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)
    Thierry Poynard
    APHP UPMC Liver Center, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie, Paris, France
    BMC Gastroenterol 10:40. 2010

Detail Information

Publications7

  1. ncbi request reprint Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients
    Patrick Ingiliz
    Hepatology Department, Pitie Salpetriere Hospital, Paris, France
    Antivir Ther 13:895-900. 2008
    ..Adefovir dipivoxil (ADV) has shown its efficacy for treating 3TC-resistant (3TC-R) HBV in HIV-coinfected patients. ADV combined with pegylated interferon (PEG-IFN) has never been evaluated in this population...
  2. doi request reprint Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy
    Patrick Ingiliz
    Hepatology Department, AP HP, GH Pitié Salpétrière, Paris, France
    Hepatology 49:436-42. 2009
    ..Conclusions: HIV-infected patients on combined antiretroviral therapy with chronic transaminase elevation of unknown origin have a high rate of liver lesions, mostly consistent with NASH related to insulin resistance...
  3. pmc Applicability and variability of liver stiffness measurements according to probe position
    Patrick Ingiliz
    AP HP Hospital Group Pitié Salpêtrière, Hepatology Department, Cedex 13, Paris 75651, France
    World J Gastroenterol 15:3398-404. 2009
    ..To investigate the liver stiffness measurement (LSM) applicability and variability with reference to three probe positions according to the region of liver biopsy...
  4. doi request reprint Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysis
    Patrick Ingiliz
    Hepatology Department, Pitie Salpetriere Hospital, Paris, France
    J Hepatol 56:49-54. 2012
    ..The course of the disease is determined by the rapidity of liver fibrosis progression (LFP). The influence of interferon on LFP in coinfected patients has yet not been evaluated by comparative liver biopsies...
  5. pmc Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers
    Thierry Poynard
    APHP Groupe Hospitalier Pitié Salpétrière, Universite Paris VI, CNRS UMR, Paris, France
    PLoS ONE 3:e3857. 2008
    ..The aim was to identify factors associated with LSM accuracy using FT as a non-invasive endpoint and vice versa...
  6. pmc An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load
    Yen Ngo
    Service d Hepato Gastroenterologie, Groupe Hospitalier Pitie Salpetriere, Universite Paris VI, CNRS UMR 8149, Paris, France
    PLoS ONE 3:e2573. 2008
    ..We compared the 4-year prognostic value of combining FT-AT and viral load for a better definition of the inactive carrier status...
  7. pmc Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)
    Thierry Poynard
    APHP UPMC Liver Center, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie, Paris, France
    BMC Gastroenterol 10:40. 2010
    ..One challenge was to use them for estimating the prevalence of fibrosis, identifying independent risk factors and to propose screening strategies in the general population...